DAMORA THERAPEUT (DMRA) Stock Price, News & Analysis
Company Description
Damora Therapeutics, Inc. develops biologic therapies for hematologic disorders, with a focus on mutant calreticulin-driven myeloproliferative neoplasms. The company’s programs address blood disorders including essential thrombocythemia and myelofibrosis, where its therapeutic work centers on disease-modifying biologics designed for patients with mutCALR-driven disease biology.
The company’s pipeline includes DMR-001 as its lead program, along with additional programs DMR-002 and DMR-003. These assets were added through the completed acquisition of privately held Damora Therapeutics in November 2025, which established the public company’s current development focus around mutCALR-targeted therapies for myeloproliferative neoplasms.
Damora operates as a biotechnology issuer rather than a diversified health-care products company. Its business model centers on research and development, regulatory preparation, and advancement of therapeutic candidates through the development pathway. Company communications describe a portfolio approach to biologics intended to cover the spectrum of patients with mutant calreticulin-driven myeloproliferative neoplasms.
Damora Therapeutics is incorporated in Delaware and lists its common stock on Nasdaq under the symbol DMRA. Regulatory records identify the company’s principal executive office in Waltham, Massachusetts. As a public biotechnology company, its recurring corporate disclosures include pipeline development, financial results, equity compensation, executive and board governance, auditor matters, and capital-structure information.
Stock Performance
DAMORA THERAPEUT (DMRA) stock last traded at $29.99. Over the past 12 months, the stock has gained 17.5%. At a market capitalization of $1.8B, DMRA is classified as a small-cap stock with approximately 61.6M shares outstanding.
DMRA Rankings
Latest News
DAMORA THERAPEUT has 7 recent news articles, with the latest published 3 days ago. Of the recent coverage, 2 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, management. View all DMRA news →
SEC Filings
DAMORA THERAPEUT has filed 5 recent SEC filings, including 2 Form SCHEDULE 13G/A, 1 Form 144, 1 Form 8-K, 1 Form SCHEDULE 13G. The most recent filing was submitted on June 22, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMRA SEC filings →
Financial Highlights
operating income reached -$210.9M, and net income was -$209.8M. Diluted earnings per share stood at $3.98. The company generated -$6.7M in operating cash flow. With a current ratio of 12.98, the balance sheet reflects a strong liquidity position.
Upcoming Events
DMR-003 regulatory submission
Proof-of-concept datasets begin
DMR-001 POC datasets begin
Options fully vest
Options expiration
DAMORA THERAPEUT has 5 upcoming scheduled events. The next event, "DMR-003 regulatory submission", is scheduled for January 1, 2027 (in 180 days). 2 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the DMRA stock price.
Short Interest History
Short interest in DAMORA THERAPEUT (DMRA) currently stands at 1.3 million shares, down 6.6% from the previous reporting period, representing 2.4% of the float. Over the past 12 months, short interest has increased by 206.4%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for DAMORA THERAPEUT (DMRA) currently stands at 3.4 days, down 18.6% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 73.7% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.9 to 5.5 days.
DMRA Company Profile & Sector Positioning
DAMORA THERAPEUT (DMRA) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #28 among all tracked companies.